Deal typeM&A & Private Equity
IndustryLife Sciences
Client nameEvestia Clinical Limited
Kester Capital completed a carve-out transaction of Evestia Clinical Limited (Evestia) in December 2024 alongside an experienced management executive management team. The business is a UK Contract Research Organisation (CRO), specialising in Rare Disease and Oncology. Evestia’s executive team has an exceptional track record of building leading CROs with a reputation for operational excellence, including at Chiltern International, a top 10 global CRO that was acquired by Labcorp in 2017 and a former Kester portfolio company.
In July 2025, Evestia acquired Atlantic Research Group (ARG). ARG has provided its clients with a wide range of clinical trial services, spanning several complex therapeutic areas for over 20 years, and has a long-standing reputation for outstanding quality of service provision.
The acquisition will expand Evestia’s US footprint, a key step in the business’s strategy to create a global, specialist CRO focused on providing pharmaceutical and biotech customers with a full suite of clinical trial services across the drug development life cycle. ARG’s expertise in neurology adds to Evestia’s specialisms in oncology and rare diseases trials.
BDO Debt Advisory successfully advised the company in raising an innovative funding package that refinanced the Kester equity bridge and allows it to efficiently access follow-on capital and re-leverage as it delivers its acquisitive growth strategy.
The BDO deal team included:
Ross McDonald, Alastair Feasey, Anish Mehta and Seb Walker
In July 2025, Evestia acquired Atlantic Research Group (ARG). ARG has provided its clients with a wide range of clinical trial services, spanning several complex therapeutic areas for over 20 years, and has a long-standing reputation for outstanding quality of service provision.
The acquisition will expand Evestia’s US footprint, a key step in the business’s strategy to create a global, specialist CRO focused on providing pharmaceutical and biotech customers with a full suite of clinical trial services across the drug development life cycle. ARG’s expertise in neurology adds to Evestia’s specialisms in oncology and rare diseases trials.
BDO Debt Advisory successfully advised the company in raising an innovative funding package that refinanced the Kester equity bridge and allows it to efficiently access follow-on capital and re-leverage as it delivers its acquisitive growth strategy.
“We would like to thank BDO Debt Advisory for their support on delivering a fantastic outcome. The flexible structure ensures that our platform is ideally placed to continue to deliver on its ambitious buy & build strategy in the coming years. We look forward to working with them again in the future.”
Thomas Holroyd, Partner, Kester Capital
The BDO deal team included:
Ross McDonald, Alastair Feasey, Anish Mehta and Seb Walker